Helping projects
change the future
APPLY NOW

News

Russian Venture Market Outlook 2019

18 January 2019

Primer Capital COO Elizaveta Rozhdestvenskaya & investment analyst Sofya Yartseva shared their expert opinion on the Russian Venture Market Outlook 2019  for  Invest-Forsight Business Magazine.

Russian Venture Market Outlook 2019

Primer Capital COO Elizaveta Rozhdestvenskaya & investment analyst Sofya Yartseva shared their expert opinion on the Russian Venture Market Outlook 2019  for  Invest-Forsight Business Magazine.
 

Primer Capital Ranked As One Of The Leading Venture Funds In Russia

27 December 2018

According to the RBC annual rating Primer Capital made it to the top 5 most active venture funds in Russia.

Primer Capital Ranked As One Of The Leading Venture Funds In Russia

According to the RBC annual rating Primer Capital made it to the top 5 most active venture funds in Russia.
 

Primer Capital’s portfolio company Bendit received the Best Technology Parade Presentation award at the ICI meeting 2018

21 December 2018

Primer Capital’s portfolio company Bendit(Israel) received the Best Technology Parade Presentation award at the ICI (Innovations in Cardiovascular Interventions) Meeting 2018 in Tel Aviv, Israel.

Primer Capital’s portfolio company Bendit received the Best Technology Parade Presentation award at the ICI meeting 2018

Primer Capital’s portfolio company Bendit(Israel) received the Best Technology Parade Presentation award at the ICI (Innovations in Cardiovascular Interventions) Meeting 2018 in Tel Aviv, Israel.
 

A day with a medicine venture capitalist

11 December 2018

Primer Capital CEO Maria Belousova and COO Elizaveta Rozhdestvenskaya for  Invest-Forsight Business Magazine.

A day with a medicine venture capitalist

Primer Capital CEO Maria Belousova and COO Elizaveta Rozhdestvenskaya for  Invest-Forsight Business Magazine.
 

Drug for Ischemic Stroke Raises $15.3 million

25 October 2018

Primer Capital’s portfolio company, Acticor Biotech (France), has closed a $15.3 million Series B round of financing from European and Asian investors. This funding will enable the company to finance the first Phase II of its antithrombotic drug for the acute phase of ischemic stroke.

Drug for Ischemic Stroke Raises $15.3 million

Primer Capital’s portfolio company, Acticor Biotech (France), has closed a $15.3 million Series B round of financing from European and Asian investors. This funding will enable the company to finance the first Phase II of its antithrombotic drug for the acute phase of ischemic stroke.
 

Primer Capital Is the Best Venture Capitalist 2018

17 October 2018

Primer Capital was awarded the «Best investment at an early stage» within the contest «National VC Awards» for investing into Botkin.AI – the clinical decision support system based on artificial intelligence technologies.

Primer Capital Is the Best Venture Capitalist 2018

Primer Capital was awarded the «Best investment at an early stage» within the contest «National VC Awards» for investing into Botkin.AI – the clinical decision support system based on artificial intelligence technologies.
 

Primer Capital Invests in the Development of Molecular Bacteriotherapy of Atopic Dermatitis

8 October 2018

Primer Capital Venture Fund invested $200K in California-based company MatriSys Bioscience. It is developing MSB-01, a commensal strain of bacteria S. hominis, that selectively kills an aggressive strain of Staphylococcus aureus that colonizes the skin of patients with atopic dermatitis (eczema). Moreover, MBS-01 helps to restore normal skin microbiome.

Primer Capital Invests in the Development of Molecular Bacteriotherapy of Atopic Dermatitis

Primer Capital Venture Fund invested $200K in California-based company MatriSys Bioscience. It is developing MSB-01, a commensal strain of bacteria S. hominis, that selectively kills an aggressive strain of Staphylococcus aureus that colonizes the skin of patients with atopic dermatitis (eczema). Moreover, MBS-01 helps to restore normal skin microbiome.
 

Primer Capital’s portfolio company, Acticor Biotech announces the signature of an Asset Transfer and Licensing agreement with CMS Medical Limited

16 August 2018

Primer Capital’s portfolio company, Acticor Biotech, France – a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism - announces the signature of an Asset Transfer and Licensing agreement with CMS Medical Limited, a wholly-owned subsidiary of China Medical System Holdings Limited ("CMS").

Primer Capital’s portfolio company, Acticor Biotech announces the signature of an Asset Transfer and Licensing agreement with CMS Medical Limited

Primer Capital’s portfolio company, Acticor Biotech, France – a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism - announces the signature of an Asset Transfer and Licensing agreement with CMS Medical Limited, a wholly-owned subsidiary of China Medical System Holdings Limited ("CMS").
 

Pilot implementation of Primer Capital’s portfolio project

4 April 2018

Botkin.AI implements its AI-based clinical decision support system into a hospital located in the Murmansk Region.

Pilot implementation of Primer Capital’s portfolio project

Botkin.AI implements its AI-based clinical decision support system into a hospital located in the Murmansk Region.
 

Startup Tour 2018

7 March 2018

60 proposals were submitted as part of the Skolkovo Startup Tour in Yuzhno-Sakhalinsk, of which 17 were approved for a face-to-face review.

Startup Tour 2018

60 proposals were submitted as part of the Skolkovo Startup Tour in Yuzhno-Sakhalinsk, of which 17 were approved for a face-to-face review.

Записи 31 - 40 of 58
First | Prev. | 2 3 4 5 6 | Next | Last